2-11-05



PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. Application Number 10/661,165 Filing Date **TRANSMITTAL** September 11, 2003 First Named Inventor **FORM** Ravinder S. DHALLAN Art Unit 1634 (to be used for all correspondence after initial filing) **Examiner Name** E. Whisenant 20 + Attorney Docket Number Total Number of Pages in This Submission 543312000420 115 Refs. ENCLOSURES (Check all that apply) After Allowance Communication Fee Transmittal Form Drawing(s) Appeal Communication to Board of Fee Attached Licensing-related Papers Appeals and Interferences Appeal Communication to TC Amendment/Reply Petition (Appeal Notice, Brief, Reply Brief) Petition to Convert to a After Final Proprietary Information **Provisional Application** Power of Attorney, Revocation Affidavits/declaration(s) Status Letter Change of Correspondence Address Other Enclosure(s) (please X Other Line. | Identify below): **Extension of Time Request** Terminal Disclaimer 1. Form PTO-1449 + copy **Express Abandonment Request** Request for Refund (16 pages) 2. 115 References Information Disclosure Statement CD, Number of CD(s) 3. Return Receipt Postcard (Supplemental - 3 pages) Certified Copy of Priority Landscape Table on CD Document(s) Reply to Missing Parts/ Remarks Incomplete Application Reply to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as Express Mail, Airbill No. EV3366 in a box addressed to: Mail Stop Amendment Commissioner for Patents P.O. Box 1450, Alexandria, VA. 22313-1450, on the control of the co	

Reg. No.

Dated: February 9, 2005

Signature:)

MORRISON & FOERSTER LLP (Customer No. 25226)

urgina (lucitos (Georgina Matos)

44,140

shown below.

Firm Name

Signature

Date

Printed name

Alicia J. Hager

February 9, 2005



CERTIFICATE OF MAILING BY "EXPRESS MAIL"

hiereby certify that this correspondence is being deposited with the United States Postal Service as express mail, Airbill No. EV336621662US, in a box addressed to: Mail Stop Amendment, Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: February 9, 2005

Diorgina hiato

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Ravinder S. DHALLAN

Serial No.: 10/661,165

Filing Date: September 11, 2003

For: METHODS FOR DETECTION OF

GENETIC DISORDERS

Examiner:

E. Whisenant

Group Art Unit:

1634

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 & 1.98

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, Virginia 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicant submits for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the foreign documents and non-patent literature are submitted herewith. The Examiner is requested to make these documents of record.

		This Supplemental Information Disclosure Statement is submitted:
		With the application; accordingly, no fee or separate requirements are required.
		Before the mailing of a first Office Action after the filing of a Request for Continued
		Examination under § 1.114. However, if applicable, a certification under 37 C.F.R. §
		1.97(e)(1) has been provided.
	\boxtimes	Within three months of the application filing date or before mailing of a first Office
		Action on the merits; accordingly, no fee or separate requirements are required.
		However, if applicable, a certification under 37 C.F.R. § 1.97(e)(1) has been provided.
		After receipt of a first Office Action on the merits but before mailing of a final Office
)		Action or Notice of Allowance.
֝֝֝֝֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֓֡		A fee is required. A check in the amount of is enclosed.
) 		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached
		to this submission in duplicate.
		A Certification under 37 C.F.R. § 1.97(e) is provided above; accordingly; no fee
		is believed to be due.
Í		After mailing of a final Office Action or Notice of Allowance, but before payment of the
ָ כ		issue fee.
ב ב		A Certification under 37 C.F.R. § 1.97(e) is provided above and a check in the
		amount of is enclosed.
		A Certification under 37 C.F.R. § 1.97(e) is provided above and a Fee Transmittal
		form (PTO/SB/17 is attached to this submission in duplicate.)

Applicant would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Supplemental Information Disclosure Statement under 37 C.F.R. § 1.97 and § 1.98 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal form is separated from this document and the Patent Office determines that an extension and/or other relief (such as payment of a fee under 37 C.F.R. §1.17(p)) is required, Applicant petitions for any required relief including extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 543312000420. However, the Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: February 9, 2005

Respectfully submitted,

Alicia J. Hage

Registration No. 44,140

Morrison & Foerster LLP 755 Page Mill Road

Palo Alto, California 94304-1018

Telephone: (650) 813-4296 Facsimile: (650) 494-0792

Form	PTO_	1440
гони	r i O-	144フ

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

Use several sheets if necessary)

	Silect 1 01 6
Docket Number 543312000420	Application Number 10/661,165
Applicant	
Ravinde	er S. DHALLAN
Filing Date September 11, 2003	Group Art Unit 1634
Mailing Date February 9, 2005	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	12/13/2001	2001/0051341	Lo et al.			
	2.	04/18/2002	2002/0045176	Lo et al.			
	3.	03/06/2003	2003/0044388	Dennis et al.			
	4.	12/18/2003	2003/0232348	Jones et al.			
	5.	06/03/2004	2004/0106102	Dhallan			
	6.	06/04/1985	4,521,509	Benkovic et al.			
	7.	04/28/1998	5,744,301	Birkenbach et al.			
	8.	01/12/1999	5,858,671	Jones			
	9.	10/12/1999	5,965,363	Monforte et al.			,
	10.	01/30/2001	6,180,372	Franzen			
	11.	07/10/2001	6,258,540	Lo et al.			
	12.	01/14/2003	6,506,561	Cheval et al.			
	12.	01/14/2003	6,506,561	Cheval et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO	
	13.	04/26/2000	EP 0 994 963	Europe				
	14.	09/25/1996	GB 2 299 166	Great Britain				
	15.	06/13/1991	WO 91/08304	WIPO				
	16.	03/02/1995	WO 95/06137	WIPO				
	17.	09/11/1998	WO 98/39474	WIPO				
	18.	01/17/2002	WO 02/04672	WIPO				
	19.	09/12/2003	WO 03/074740	WIPO				
	20.	12/24/2003	WO 03/106642	WIPO				
	21.	09/16/2004	WO 2004/078994	WIPO				
	22.	09/16/2004	WO 2004/079011	WIPO				

EXAMINER: DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Sheet 2 of 8 Docket Number 543312000420 Application Number 10/661,165 Form PTO-1449 Applicant INFORMATION DISCLOSURE CITATION Ravinder S. DHALLAN IN AN APPLICATION (Use several sheets if necessary) Filing Date September 11, 2003 Group Art Unit 1634 Mailing Date February 9, 2005 OTHER DOCUMENTS (including author, title, Date, Pertinent Pages, Etc.) Ref. Title Examiner **Initials** No. Amicucci, P. et al. (2000). "Prenatal Diagnosis of Myotonic Dystrophy Using Fetal DNA Obtained 23. from Maternal Plasma," Clinical Chemistry 46(2):301-302. Angert, R.M. et al. (January 2003). "Fetal Cell-Free Plasma DNA Concentrations in Maternal Blood 24. Are Stable 24 Hours after Collection: Analysis of First- and Third-Trimester Samples," Clinical Chemistry 49(1):195-198. 25. Anker, P. et al. eds. (April 2000). "Circulating Nucleic Acids in Plasma or Serum," Table of Contents from the First International Symposium on Circulating Nucleic Acids in Plasma/Serum: Implication in Cancer Diagnosis, Prognosis, or Follow-up and in Prenatal Diagnosis, April 18-20, 1999 in Menthon Saint-Bernard, France, located at http://www.unige.ch/LABPV/symposium/cnaps/cnaps book.html> last visited on March 27, 2001, four pages. Anonymous. (2001). "Methods of Ultrasensitive Bioanalysis: DNA Sequencing and Indexing" Union 26. Bay Ultrasensitive Bioanalysis Team located at http://faculty.washington.edu/dovichi/research/application/DNA/DNASequencing.html last visited April 16, 2001, four pages. 27. Anonymous. (2001). "Molecular Indexing (MI) Home Page," Helix Research Institute located at http://www.hri.co.jp/MI last visited April 16, 2001, four pages. Anonymous. (December 16, 1996). "Birth Defects: Maternal Blood Gets Put to the Test," Physician's 28. Weekly Clinical Updates located at: http://www.physweekly.com/archive/96/12 16 19/cu4.html> last visited on March 27, 2001, one page. 29. Anonymous. (December 17, 1998). "Strategies for the Rapid Prenatal Detection of Down's Syndrome," CMGS located at http://www.ich.ucl/ac/uk/cmgs/downs98.html last visited on March 27, 2001, four pages. Barnett, E.V. (June 1968). "Detection of Nuclear Antigens (DNA) in Normal and Pathologic Human 30. Fluids by Quantitative Complement Fixation," Arthritis and Rheumatism 11(3):407-417. 31. Bauer, M. et al. (January 2002), "Detection of Maternal Deoxyribonucleic Acid in Umbilical Cord Plasma by Using Fluorescent Polymerase Chain Reaction Amplification of Short Tandem Repeat Sequences," Am. J. Obstet. Gynecol. 186:117-120. 32. Beer, A.E. et al. (September 7, 1994). "The Biological Basis of Passage of Fetal Cellular Material into the Maternal Circulation," Annals New York Academy of Sciences 731:21-35. Bennett, P.R. et al. (August 26, 1993). "Prenatal Determination of Fetal RhD Type by DNA 33. Amplification," The New England Journal of Medicine 329(9):607-610.

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	9	Docket Number 543312000420	Application Number 10/661,165	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Ravinder S. DHALLAN		
	(Use several sheets if necessary)	Filing Date September 11, 2003	Group Art Unit 1634	
		Mailing Date February 9, 2005		
34.	Bianchi, D.W. (December 1995). "Pro The Journal of Pediatrics 127(6):847		Fetal Cells in Maternal Blood,"	
35.	Bianchi, D.W. (1998). "Current Know <i>Perinat. Med.</i> 26:175-185.	vledge About Fetal Blood Cells	in the Maternal Circulation," J.	
36.	Bianchi, D.W. (1998). "Fetal DNA in Thins," Am. J. Hum. Genet. 62:763-7		ckens and the Placental Barrier	
37.	Bianchi, D.W. (2000). "A Guest Editor Dilemma," Obstetrical and Gynecolo		ernal Blood: Diagnosis or	
38.	Bianchi, D.W. (September 2000). "Fe Associated with Fetal Cell Microchin Reproductive Biology 92:103-108.			
39.	Bianchi, D.W. (May 2002). "Prenatal Plasma Analysis Precede Invasive Te			
40. Bianchi, D.W. et al. (2001). "Longitudinal Fetal DNA Quantitation Studies in Maternal Cells a Plasma over a 24 Hour Period," Program Nr: 2377 located at http://www.faseb.org/genetics/ashg00/f2377.html last visited on March 27, 2001, one page.				
41.	Bianchi, D.W. et al. (2001). "Thoughts on the Origin of Fetal DNA in the Pregnant Woman," Abstract 3.4 In Chapter 3 "Clinical Applications of Fetal DNA in Maternal Plasma," In Abstracts, 12th Fetal Cell Workshop, Fetal Diagn. Ther., 16:450.			
. 42.	Bianchi, D.W. et al. (July 2002). "Fetal Gender and Aneuploidy Detection Using Fetal Cells in Maternal Blood: Analysis of NIFTY I Data," <i>Prenatal Diagnosis</i> 22:609-615.			
43.	Brambati, B. (September 7, 1994). "P Red Cells: Dream or Reality?" <i>Annal.</i>			
44.		etal DNA Quantitation in Peripheral Blood Is Not Useful as a en with Preeclampsia," <i>Hypertens Pregnancy</i> 22(2):157-164.		
45.	Camaschella, C. et al. (June 1, 1990). Disease on Maternal Peripheral Blood). "Prenatal Diagnosis of Fetal Hemoglobin Lepore-Boston od," <i>Blood</i> 75(11):2102-2106.		
46.	Chen, X.Q. et al. (September 1996). Cancer Patients," <i>Nature Medicine</i> 2(asma DNA of Small Cell Lung	
47.	Cohen, J. (October 2002). "Fetal Fort	unes," Technology Review 54-6	51.	
48.	48. Cox, R.A. et al. (February 1977). "DNA Concentrations in Serum and Plasma," <i>Clinical Chemi</i> 23(2):297.			
49.	Davis, G.L. et al. (Jan-Feb, 1973). "I electrophoresis (CIE)," Arthritis and		y Counterimmuno-	
EXAMINER:	, , , , , , , , , , , , , , , , , , , 	DATE CONSIDERED:		
	nitial if citation considered, whether or not the cital I not considered. Include a copy of this form with		a line through the citation if not in	

Form PTO-1449	Form PTO-1449		Application Number 10/661,165	
	ION DISCLOSURE CITATION AN APPLICATION	Applicant Ravinder S. DHALLAN		
	lse several sheets if necessary)	Filing Date September 11, 2003	Group Art Unit 1634	
,		Mailing Date February 9, 2005		
50.	Dhallan, R. et al. (March 3, 2004). "M Recovered From the Maternal Circular			
51.	Ding, C. et al. (July 20, 2004). "MS A Acids: Application to Noninvasive Pression."			
52.	Douglas, G.W. et al. (November 1959) American Journal of Obstetrics and G		g Blood During Pregnancy,"	
53.	Emanuel, S.L. et al. (1993). "Amplific 10(6):144-146.	ation of Specific Gene Products	from Human Serum," GATA	
54.	Farnia, A. et al. (1998). "Fetal Cells in Down Syndrome Screening," <i>Prenat.</i>		on-Invasive Step for Fetal	
55.	Fournié, G.J. et al. (1993). "Plasma Dl 39:215-221.	NA as Cell Death Marker in Eld	erly Patients," Gerontology	
56.	Fowke, K.R. et al. (1995). "Genetic As Serum or Plasma," <i>Journal of Immuno</i>		red From Minute Amounts of	
57. Hahn, S. et al. (September 2002). "Prenatal Diagnosis Using Fetal Cells and Cell-Free F Maternal Blood: What is Currently Feasible?" Clinical Obstetrics and Gynecology 45(3)				
58.	Hahn, S. et al. (2001). "An Examination Basel Experience," Abstract 3.2 In Ch Plasma," In Abstracts, 12th Fetal Cell	apter 3 "Clinical Applications of	f Fetal DNA in Maternal	
59.	Heinemann, J.A. et al. (April 2000). "I Genes," Annals New York Academy of		Nature of Horizontally Mobile	
60.	Holzgreve, W. et al. (2000). "Fetal Ce Obstetrics and Gynaecology 14(4):709	Cells in Cervical Mucus and Maternal Blood," Bailliere's Clinical 109-722.		
61.	Holzgreve, W. et al. (June 2001). "Pre Maternal Blood," Clinical Perinatolog	renatal Diagnosis Using Fetal Cells and Free Fetal DNA in ogy 28(2):353-365.		
62.	International Search Report mailed on PCT/US03/06376 filed on February 23		Application No.	
63.	Kamm, R.C. et al. (1972). "Nucleic Ad Chemistry 18(6):519-522.	cid Concentrations in Normal H	uman Plasma," <i>Clinical</i>	
64.		Deoxyribonucleic Acid Concentrations of Women in Labor and all of Obstetrics and Gynecology 121(1):29-31.		
65.	Kang, A. et al. (1999). "Fetal Cells in and in the Etiology of Certain Disease eine nicht-invasive pränatale Diagnost Med. Wochenschr 129:1470-1743. En	es," ("Fetale Zellen im mütterlich ik und bei der Ätiologie bestimt	hen Blut - ihre Bedeutung für nter Erkrankungen,") Schweiz	
		D. ME CONSTRUCT		
EXAMINER:		DATE CONSIDERED:		
	ial if citation considered, whether or not the citati not considered. Include a copy of this form with r		line through the citation if not in	

Form PTO-1449		Docket Number 543312000420	Application Number 10/661,165	
INFORMATION DISCLOSURE CITATION		Applicant		
IN AN APPLICATION		Ravinder S. DHALLAN		
(U	Jse several sheets if necessary)	Filing Date September 11, 2003	Group Art Unit 1634	
		Mailing Date February 9, 2005		
66.	Kuo, P-L. (1999). "Fetal Cell Isolation Adv. Obstet. Perinatol. 10(1):15-24.	From Maternal Blood - Clinica	l and Biological Implications,"	
67.	Kwak, J.Y.H. et al. (September 7, 199 in the Induction of the Antiphospholip Annals New York Academy of Sciences	id Antibody Syndrome and Reco		
68.	Lagona, F. et al. (April 2000). "Fetal D Cells," Annals New York Academy of S		asma and Nucleated Blood	
69.	Lee, T. et al. (November 2002). "Down Serum," Am. J. Obstet. Gynecol. 187:		DNA in Archived Maternal	
70.	Leon, S.A. et al. (1977). "Free DNA in Rheumatology 4(2):139-143.	the Serum of Rheumatoid Arth	ritis Patients," Journal of	
71.	Lo, Y.M.D. (September 7, 1994). "An from Maternal Peripheral Blood," Ann.			
72.		94). "Strategies for the Detection of Autosomal Fetal DNA l Blood," <i>Annals New York Academy of Sciences</i> 731:204-213.		
73.	Lo, Y.M.D. (September 7, 1994). "Pre Amplification of Peripheral Blood of F Sciences, 731: 229-236.			
74. Lo, Y.M.D. (December 1994) "Non-Invasive Prenatal Diagnosis Using Fetal Cells in Materna Blood," <i>Journal of Clinical Pathology</i> 47(12):1060-1065.				
75.	Lo, Y.M.D. (1999). "Fetal RhD Genot 312.	yping From Maternal Plasma," A	Annals of Medicine 31(5):308-	
76.	Lo, Y.M.D. (1999). "Rapid Clearance 64:218-224.	of Fetal DNA from Maternal Pla	asma," Am. J. Hum. Genet.	
77.	Lo, Y.M.D. (April 2000). "Fetal DNA Sciences 906:141-147.	in Maternal Plasma," Annals of	New York Academy of	
78.	Lo, Y.M.D. (December, 2000). "Fetal Applications," Clinical Chemistry 46(gy and Diagnostic	
79.		Maternal Plasma," Abstract 3.1 In Chapter 3 "Clinical ernal Plasma," In Abstracts, 12th Fetal Cell Workshop, Fetal		
80.	Lo, Y.M.D. (June 2001). "Fetal DNA is Genotyping of the Fetus," <i>Transfus. Ca</i>	A in Maternal Plasma: Application to Non-Invasive Blood Group Clin. Biol. 8(3):306-310.		
81.	Lo, Y.M.D. (January 2003). "Fetal DN <i>Research</i> 53(1):16-17.	IA in Maternal Plasma/Serum: 1	The First 5 Years," Pediatric	
DIV. 2		DATE COMMENTED		
EXAMINER:		DATE CONSIDERED:		
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.				

Form PTO-1449)	Docket Number 543312000420	Application Number 10/661,165		
INFORMATION DISCLOSURE CITATION		Applicant			
. 1	N AN APPLICATION	Ravinder S. DHALLAN			
	(Use several sheets if necessary)	Filing Date September 11, 2003	Group Art Unit 1634		
		Mailing Date February 9, 2005			
82.	Lo, Y.M.D. et al. (June 16, 1990). "De Blood," <i>The Lancet</i> 335:1463-1464.	etection of Single-Copy Fetal DN	JA Sequence From Maternal		
83.	Lo, Y.M.D. et al. (1994). "Detection of RhD-Negative Women," <i>British Journ</i>		ipheral Blood of Sensitized		
84.	Lo, Y.M.D. et al. (1999). "Increased F Carrying Fetuses with Trisomy 21," C				
85.	Longo, M.C. et al. (1990). "Use of Ura Polymerase Chain Reactions," <i>Gene</i> 9		l Carry-Over Contamination in		
86.	Martin, M. et al. (February 1992). "A HLA Typing," <i>Human Immunology</i> 33		ma as a Source of DNA for		
87.	Miller, D. ed. (August 16, 1996). "Not published and located at http://iubio.				
88.	Mulcahy, H.E. et al. (September 7, 19 348(9028):628.	1996). "Cancer and Mutant DNA in Blood Plasma," The Lancet			
89.	Muller, F. et al. (March 2000). "Paren Fetal Trisomy 21," Hum. Genet. 106::		ome in Prenatally Diagnosed		
90.	Nawroz, H. et al. (September 1996). "Microsatellite Alterations in Serum DNA of Head and Neck Cancer Patients," <i>Nature Medicine</i> 2(9):1035-1037.				
91.		Pertl, B. et al. (May 14, 1994). "Rapid Molecular Method for Prenatal Detection of Down's Syndrome," <i>The Lancet</i> 343:1197-1198.			
92.	Pertl, B. et al. (October 1999). "First T Circulation," Seminars in Perinatolog		tal Cells in the Maternal		
93.	Pertl, B. et al. (January 6, 2000). "Det Multiplex Fluorescent Polymerase Characteristics." 106:45-49.				
94. Pertl, B. et al. (March 27, 2001). "Detection of Male and Female Fetal DNA in Maternal Plasma Multiplex Fluorescent Polymerase Chain Reaction Amplification of Short Tandem Repeats," loc at http://link.springer.de/link/service/journals/00439/contents/99/00166/s004399900166ch002.last visited on March 27, 2001, one page.					
Pertl, B. et al. (March 27, 2001). "Detection of Male and Female Fetal DNA in Maternal Plasma Multiplex Fluorescent Polymerase Chain Reaction Amplification of Short Tandem Repeats (STI Program Nr: 410 located at http://www.faseb.org.genetics/ashg99/f410.html last visited Marc 2001, one page.					
96.	Poon, L.L.M. (2000). "Presence of Fe	al RNA in Maternal Plasma," C	lin. Chem. 46(11):1832-1834.		
EXAMINER:		DATE CONSIDERED:			
EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.					

Form PTO	-1449		Docket Number 543312000420	Application Number 10/661,165		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant Ravinder S. DHALLAN			
(Use several sheets if necessary)			Filing Date September 11, 2003	Group Art Unit 1634		
			Mailing Date February 9, 2005	<u> </u>		
	97.	Poon, L.L.M. et al. (November 25, 200 Maternal Plasma," <i>The Lancet</i> 356:18		Down's Syndrome from		
	98.	Poon, L.L.M. et al. (November 2001). Chimmica Acta 313:151-155.	"Circulating Fetal DNA in Mate	ernal Plasma," <i>Clinica</i>		
	99.	Ramster, B. (July 2, 2001). "IVF Screet located at http://news.bmn,com/news				
	100.	Raptis, L. et al. (December 1980). "Qu Patients with Systemic Lupis Erythems				
	101.	Samura, O. et al. (July 2000). "Female Prove Origin," <i>Hum. Genet.</i> 107:28-32		Use of DNA Polymorphisms to		
	102.	Samura, O. et al. (September 2001). "I Maternal Blood by Use of Short Tande				
	103.	Shapiro, B. et al. (1983). "Determination Malignant Gastrointestinal Disease," (1983).		n Patients with Benign or		
	104.	Sidransky, D. (April 2000). "Circulating DNA: What We Know and What We Need to Learn," <i>In</i> Circulating Nucleic Acids in Plasma or Serum, <i>Annals New York Academy of Sciences</i> 906:1-4.				
	105.	Simpson, J.L. et al. (1994). "Isolating Fetal Cells in Maternal Circulation for Prenatal Diagnosis," <i>Prenatal Diagnosis</i> 14:1229-1242.				
	106.	Simpson, J.L. et al. (September 7, 1994). "Fetal Cells in Maternal Blood. Overview and Historical Perspective," <i>Annals New York Academy of Sciences</i> 731:1-8.				
	107.	Simpson, J.L. et al. (March 3, 2004). " 1137.	Cell-Free Fetal DNA in Materna	al Blood," JAMA 291(9):1135-		
	108.	Smid, M. et al. (1999). "Evaluation of Plasma and Nucleated Blood Cells," C				
	Smid, M. et al. (2001). "Quantitative Analysis of Fetal DNA in Maternal Plasma in Pregnancies Affected by Insulin-Dependent Diabetes mellitus (IDDM)," Abstract 3.3 In Chapter 3 "Clinical Applications of Fetal DNA in Maternal Plasma," In Abstracts, 12th Fetal Cell Workshop, Fetal Diagn. Ther., 16:449-450.					
	110.	SNP Entry Report for HC21S00007. (I bin/csnp_fetch?entry=HC21S00007>				
	111. SNP Entry Report for HC21S00027. (Date Unknown). located at http://csnp.unige.ch/cgi-bin/csnp_fetch?db+csnp&format=html&entry=HC21S00027 last visited on September 27, 2004, one page.					
	112.	2. SNP Entry Report for HC21S00131. (Date Unknown). located at http://csnp.unige.ch/cgi-bin/csnp_fetch?db+csnp&format=html&entry=HC21S00131 last visited on September 27, 2004, one page.				
EXAMIN	VER:		DATE CONSIDERED:			
		al if citation considered, whether or not the citation considered. Include a copy of this form with n		line through the citation if not in		

Form PTO-1449		Docket Number 543312000420	Application Number 10/661,165	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant Ravinder S. DHALLAN		
	Jse several sheets if necessary)	Filing Date September 11, 2003	Group Art Unit 1634	
		Mailing Date February 9, 2005		
113.	SNP Entry Report for HC21S00340. (bin/csnp_fetch?entry=HC21S00340>			
114.	Steele, C.D. et al. (December 1996). 'Peripheral Blood: A Review," Clinic			
115.	Strickland, S. et al. (October 30, 1992	2). "Invasion of the Trophoblasts	s," Cell 71:355-357.	
116.	Stroun, M. et al. (April 2000). "The Academy of Sciences 906:161-168.	Origin and Mechanism of Circu	lating DNA," Annals New York	
117.	Tan, E.M. et al. (1966). "Deoxyribone Patients with Systemic Lupis Erythen			
118.	Tang, N.L.S. et al. (1999). "Detection Polymorphisms in Maternal Plasma,"			
119.		1994). "The Time of Appearance, and Quantitation, of Fetal DNA Is New York Academy of Sciences 731:217-225.		
120.	120. Uitto, J. et al. (August 2003). "Probing the Fetal Genome: Progress in Non-Invasive Prenatal Diagnosis," <i>Trends in Molecular Medicine</i> 9(8):239-243.			
121.	van Wijk, I.J. et al. (2000). "Detection Clinical Chemistry 46(5):729-731.	n of Apoptotic Fetal Cells in Pla	sma of Pregnant Women,"	
122.	Velculescu, V.E. et al. (October 2000). "Analysing Uncharted Transcriptomes with SAGE," <i>TIG</i> 16(10): 423-425.			
123.	Verma, L. et al. (July 4, 1998). "Rapid The Lancet 352:9-11.	d and Simple Prenatal DNA Dia	ignosis of Down's Syndrome,"	
124.		3). "Maternal Serum Cell-Free Fetal DNA Levels are Increased in my 18," <i>Hum. Genet.</i> 112(1):204-208.		
125.	Yamamoto et al. (March 1994). "Anti Oceania J. Obstet Gynaecol. 20(1):93		s in Preeclampsia," Asia	
126.	Zhen, D.K. et al. (1998). "Poly-Fish: Cytogenetic Analysis of Fetal Cells in			
Zhong, X.Y. et al. (2000). "Fetal DNA in Maternal Plasma is Elevated in Pregnancies with Anel Fetuses," <i>Prenatal Diagnosis</i> 20:795-798.				
		,		
EXAMINER:		DATE CONSIDERED:		
EXAMINER: Init	ial if citation considered, whether or not the citat	tion conforms with MPEP 609. Draw a	line through the citation if not in	

conformance and not considered. Include a copy of this form with next communication to applicant.